Items where authors include "Leigh, P.N."

Article

Alarcan, H. orcid.org/0009-0002-8788-2773, Bruno, C., Emond, P. et al. (20 more authors) (2024) Pharmacometabolomics applied to low‐dose interleukin‐2 treatment in amyotrophic lateral sclerosis. Annals of the New York Academy of Sciences, 1536 (1). pp. 82-91. ISSN 0077-8923

Currò, R., Dominik, N., Facchini, S. et al. (155 more authors) (2024) Role of the repeat expansion size in predicting age of onset and severity in RFC1 disease. Brain, 147 (5). pp. 1887-1898. ISSN 0006-8950

Balendra, R., Jones, A.R., Al Khleifat, A. et al. (7 more authors) (2023) Comparison of King’s clinical staging in multinational amyotrophic lateral sclerosis cohorts. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24 (1-2). pp. 71-81. ISSN 2167-8421

Giovannelli, I., Bayatti, N., Brown, A. et al. (23 more authors) (2021) Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 3 (3). fcab141. ISSN 2632-1297

Camu, W., Mickunas, M., Veyrune, J.-L. et al. (18 more authors) (2020) Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 59. 102844. ISSN 2352-3964

van Eijk, R.P.A., Nikolakopoulos, S., Roes, K.C.B. et al. (7 more authors) (2019) Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. Journal of Neurology, Neurosurgery & Psychiatry, 90 (12). pp. 1331-1337. ISSN 0022-3050

Al-Chalabi, A., Shaw, P. orcid.org/0000-0002-8925-2567, Leigh, P.N. et al. (6 more authors) (2019) Oral levosimendan in amyotrophic lateral sclerosis : a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Psychiatry, 90 (10). pp. 1165-1170. ISSN 0022-3050

van Eijk, R.P.A., Jones, A.R., Sproviero, W. et al. (19 more authors) (2017) Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 89 (18). pp. 1915-1922. ISSN 0028-3878

McLaughlin, R.L., Schijven, D., van Rheenen, W. et al. (433 more authors) (2017) Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 8. 14774.

Kenna, K.P., van Doormaal, P.T.C., Dekker, A.M. et al. (92 more authors) (2016) NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 48 (9). pp. 1037-1042. ISSN 1061-4036

Fogh, I., Lin, K., Tiloca, C. et al. (46 more authors) (2016) Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 73 (7). pp. 812-820. ISSN 2168-6149

Gaastra, B., Shatunov, A., Pulit, S. et al. (15 more authors) (2016) Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17 (7-8). pp. 593-599. ISSN 2167-8421

van der Kleij, L.A., Jones, A.R., Steen, I.N. et al. (6 more authors) (2015) Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration , 16 (7-8). pp. 442-447. ISSN 2167-8421

Balendra, R., Jones, A., Jivraj, N. et al. (6 more authors) (2014) Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 86 (1). pp. 45-49. ISSN 0022-3050

Al-Chalabi, A., Shaw, P.J., Young, C.A. et al. (7 more authors) (2011) Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurology, 11. 111. ISSN 1471-2377